Transcript: ESMO Congress 2025 key takeaways
Li Zhang, MD
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
- This year ESMO, we see a lot of very good randomised phase three studies. I think, for example, we see the ivonescimab which is the VEGF plus PD-1 bispecific modern white bodies in the squamous cell carcinomas, was positive trials that we see a HER2 TKI for the HER2 exon 20 mutation, which is also very impressive result. We see a lot of [Indistinct] tools studies, the overall survival benefit. I think this all randomised phase three studies, are all new data that will really change our daily practice. I think this is very impressive for me.